Rights Issue Offer Document
Rights Issue Offer Document
Melbourne, June 5, 2017 AEST (ABN Newswire) - This Offer Booklet relates to an Offer of New Shares to Eligible Shareholders of Bluechiip Limited (ASX:BCT) (Bluechiip or the Company) by way of a nonrenounceable rights issue. This Offer Booklet is dated 5 June 2017 and was lodged with ASX on that date. The ASX does not take any responsibility for the contents of this Offer Booklet.

To view the Offer Booklet, please visit:

About Bluechiip Ltd

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at http://www.bluechiip.com



Andrew McLellan
Managing Director & CEO
Bluechiip Limited
Tel: +61-3-9763-9763
Mob: +61-457-823-470
Email: andrew.mclellan@bluechiip.com

Related Companies

Bluechiip Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 12) (Last 30 Days: 56) (Since Published: 1665) 

Bluechiip Ltd NEWS: RECENT VISITS (2537)

Research Report

Social Media